Monte Rosa Therapeutics promotes three executives to CSO, CBO/CLO, and COO

Monte Rosa Therapeutics, Inc.

Sharon Townson, Ph.D., promoted to Chief Scientific Officer; previously CTO.
Phil Nickson, Ph.D., J.D., promoted to Chief Business and Legal Officer; previously General Counsel.
Jennifer Champoux promoted to Chief Operating Officer; previously Chief People and Operations Officer.
All promotions effective immediately as of May 30, 2024.
No departures announced; internal promotions reflect pipeline and platform advancement.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Jennifer Champoux

Chief Operating Officer

GLUE · Monte Rosa Therapeutics, Inc.

Effective: 2024-05-28
Filed: May 30, 2024, 7:59 PM ET

On May 28, 2024, the Compensation, Nomination and Corporate Governance Committee of Board of Directors of Monte Rosa Therapeutics, Inc. (the “Company”) promoted Jennifer Champoux, the Company’s Chief People and Operations Officer, to serve as the Company’s Chief Operating Officer, effective as of May 28, 2024

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jennifer Champoux changed role as Chief Operating Officer at Monte Rosa Therapeutics, Inc..

Action: promoted
Role: Chief Operating Officer

Exact text from the filing

On May 28, 2024, the Compensation, Nomination and Corporate Governance Committee of Board of Directors of Monte Rosa Therapeutics, Inc. (the “Company”) promoted Jennifer Champoux, the Company’s Chief People and Operations Officer, to serve as the Company’s Chief Operating Officer, effective as of May 28, 2024

View on SEC.gov

Monte Rosa Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-149802

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.